» Articles » PMID: 11847219

Up-regulation of Prostaglandin E2 Synthesis by Interleukin-1beta in Human Orbital Fibroblasts Involves Coordinate Induction of Prostaglandin-endoperoxide H Synthase-2 and Glutathione-dependent Prostaglandin E2 Synthase Expression

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2002 Feb 16
PMID 11847219
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Prostaglandin E(2) (PGE(2)) production involves the activity of a multistep biosynthetic pathway. The terminal components of this cascade, two PGE(2) synthases (PGES), have very recently been identified as glutathione-dependent proteins. cPGES is cytoplasmic, apparently identical to the hsp90 chaperone, p23, and associates functionally with prostaglandin-endoperoxide H synthase-1 (PGHS-1), the constitutive cyclooxygenase. A second synthase, designated mPGES, is microsomal and can be regulated. Here we demonstrate that mPGES and PGHS-2 are expressed at very low levels in untreated human orbital fibroblasts. Interleukin (IL)-1beta treatment elicits high levels of PGHS-2 and mPGES expression. The induction of both enzymes occurs at the pretranslational level, is the consequence of enhanced gene promoter activities, and can be blocked by dexamethasone (10 nm). SC58125, a PGHS-2-selective inhibitor, could attenuate the induction of mPGES, suggesting a dependence of this enzyme on PGHS-2 activity. IL-1beta treatment activates p38 and ERK mitogen-activated protein kinases. Induction of both mPGES and PGHS-2 was susceptible to either chemical inhibition or molecular interruption of these pathways with dominant negative constructs. These results indicate that the induction of PGHS-2 and mPGES by IL-1beta underlies robust PGE(2) production in orbital fibroblasts.

Citing Articles

Fibrocyte Participation in Thyroid-Associated Ophthalmopathy Suggests New Approaches to Therapy.

Smith T Ophthalmic Plast Reconstr Surg. 2023; 39(6S):S9-S18.

PMID: 38054981 PMC: 10703002. DOI: 10.1097/IOP.0000000000002509.


Establishment and Comparison of Two Different Animal Models of Graves' Orbitopathy.

Wang W, Zhang J, Qin Y, Li H, Dai Y, Li H Transl Vis Sci Technol. 2023; 12(6):12.

PMID: 37342053 PMC: 10289271. DOI: 10.1167/tvst.12.6.12.


Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease.

Smith T J Clin Endocrinol Metab. 2022; 107(Suppl_1):S13-S26.

PMID: 36346686 PMC: 9359447. DOI: 10.1210/clinem/dgac328.


Dihydroartemisinin Exerts Antifibrotic and Anti-Inflammatory Effects in Graves' Ophthalmopathy by Targeting Orbital Fibroblasts.

Yang S, Wang X, Xiao W, Xu Z, Ye H, Sha X Front Endocrinol (Lausanne). 2022; 13:891922.

PMID: 35663306 PMC: 9157422. DOI: 10.3389/fendo.2022.891922.


Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.

Smith T Front Endocrinol (Lausanne). 2021; 11:610337.

PMID: 33391187 PMC: 7774640. DOI: 10.3389/fendo.2020.610337.